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donor sources.
A risk-adapted treatment strategy is crucial to improve
the outcome of pts with HRHD. Our policy is to offer a hap-
loidentical HCT to adult pts lacking a matched donor in the
appropriate time according to clinical indications
(www.leukemianet.org, www.ebmt.org). This policy is inte-
grated in ongoing protocols for primary disease.
Methods: Here we are reporting the intention-to-treat
(ITT) analysis of HCT in all consecutive HRHD pts
referred to our Institution between January 2004 and
June 2012.
Results: Indication to HCT was given to 611 pts (median age
49 y, range 10-76; male 394), 120 pts (20%) received
a transplant from a MRD; 187 pts (30%) activated a MUD
search; 118 pts (19% of total pts, 63% of MUD searching)
received a MUD transplant; 12 pts (2%) received a umbilical
cord blood unit. Overall, 237 pts received a haplo-HCT (49%).
The median time from indication to HCT was 87 days. The
median time from indication to activation was 12 days and
the median time from activation to HCT was 114 days (range
22-824). Lack of donor was not a limiting factor. Age was not
a limiting variable to HCT execution: 107 patients (out of 487
SCT e 22%) were in the 60-69 range of age. The overall
survival (OS) analysis in ITT for the entire populationwas 43%
at 2 years, with a median time of survival of 767 days. The
2yOS in pts transplanted in CRwas 60%, in pts transplanted in
PD is 25% (p <0.001).
The OS according to donor source (MRD vs MUD vs
haplo-HCT) was comparable (p¼ns) in pts transplanted in
CR.
The 2-year OS in pts affected by acute myeloid leukemia
was 66%, 60% and 13% for patients transplanted in CR1, >CR1
and PD, respectively. The outcome analysis (OS, relapse
incidence, transplant related mortality) per donor source
was comparable (p¼ns) within CR setting.
Conclusion: For many pts with HRHD, HCT from a MRD
provides the best chance for long-term survival. However,
only approximately 30% of individuals have a MRD. In our
experience, haplo-HCT offers a concrete option of cure to
HRHD pts: outcome results are superimposable to MRD
and MUD in pts in CR at HCT. In ITT analysis, 80% of
candidate pts received an HCT as a potential immuno-
therapy. All patients affected by HRHD, for whom an HCT
is part of their therapeutic program, should proceed with
a well-timed HCT whatever the stem cell source, and in
the absence of a fully HLA-compatible donor the option of
a haploidentical donor should be simultaneously consid-
ered.27
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Introduction: Reduced intensity conditioning (RIC) alloge-
neic hematopoietic cell transplantation (HCT) with alemtu-
zumab, ﬂudarabine, and melphalan can be associated with
high incidences of mixed chimerism (MC). We have previ-
ously observed a signiﬁcant effect of dose and timing of
alemtuzumab on incidences of MC in patients with HLH.
Here we sought to determine the effects of alemtuzumab
schedule and dose on chimerism in a large cohort of patients
treated with RIC.
Methods: We performed 187 RIC HCT in 186 pediatric
patients between 2004 and March, 2012. Fourteen patients
were excluded because of regimen alterations due to
illness or intolerance (n¼13) or malignancy relapse (n¼1).
All patients received ﬂudarabine 150mg/M2 (1mg/kg if
<10kg) divided over days -8 to -4 or -7 to -3, and
melphalan 140mg/M2 (4.7mg/kg if <10kg) on day -3 or -2.
RIC HCT procedures were divided into 3 groups based
upon the timing and dose of alemtuzumab. The distal
group received alemtuzumab with a dose escalation
schedule of 3mg/10mg/15mg/20mg or 3mg/10mg/10mg/
10mg starting on day -23, -22, or -21. The intermediate
group received 1mg/kg alemtuzumab divided over 5 days
starting on day -14. The proximal group received alem-
tuzumab beginning on days -12, -11, -9 or -8, with either
of the dosing schemas. The distal group was further
subdivided based on cumulative alemtuzumab doses of
greater or less than 3mg/kg (the median dose/kg). The
cumulative incidences (CI) of MC were compared.
Results: A 75% CI of MC was observed in the proximal
group, versus 32% and 39% of patients treated with the
intermediate and distal schemas (p<0.0001). Within the
distal group, the CI of MC was 67% in patients who received
>3mg/kg and 28% in patients who received <3mg/kg
(p¼0.008).
Conclusion: Proximal dosing of alemtuzumab with relation
to graft infusion and higher doses of alemtuzumab signiﬁ-
cantly increase the incidence of mixed chimerism.28
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Radioimmunotherapy (RIT) has been employed to
decrease relapse after hematopoietic cell transplantation
Table 1
Univariable outcomes of patients who underwent allogeneic HSCT for AML,
ALL, CML, MDS who had IFI w/in 12 months pre-transplant vs. no docu-
mented IFI w/in 12 months prior to transplant (2001 to 2009)
Outcomes Pre-tx invasive
fungal infection
All others P-value
N
Eval
Probability
(95% CI)
Probability
(95% CI)
Overall survival
from transplant
825 10247
@ 1 year 54 (48-55)% 65 (64-66)% <.0001
@ 3 years 35 (31-38)% 50 (49-51)% <.0001
@ 5 years 30 (26-34)% 45 (44-46)% <.0001
Relapse 813 10146
@ 1 year 33 (29-36)% 26 (25-27) % 0.0002
@ 3 years 42 (39-46)% 35 (34-36)% <.0001
@ 5 years 45 (41-49)% 39 (38-40)% 0.0018
Treatment
related mortality
813 10146
@ 1 year 23 (20-26)% 17 (17-18)% 0.0003
@ 3 years 27 (24-30)% 22 (21-23)% 0.0046
@ 5 years 29 (26-32)% 25 (24-26)% 0.0347
Disease
free survival
813 10146
@ 1 year 45 (41-48)% 57 (56-58)% <.0001
@ 3 years 31 (28-34)% 44 (43-45)% <.0001
@ 5 years 27 (23-31)% 37 (36-38)% <.0001
Acute GVHD
(grade 2-4)
822 10224
@ 100 days 34 (31-37)% 39 (38-40)% 0.0022
Chronic GVHD 810 10098
@ 1 year 31 (28-34)% 39 (38-40) % <.0001
@ 3 years 35 (32-38)% 44 (43-45)% <.0001
@ 5 years 36 (32-39)% 45 (44-46)% <.0001
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antibody (Ab) accretion at tumor sites and gradual elim-
ination from circulation. We have used a pretargeted (P)
RIT approach employing the high-afﬁnity streptavidin
(SA)-biotin system, in which an anti-CD45 Ab-SA conju-
gate and the radioactive DOTA-biotin compound are
administered separately. After maximal accumulation of
Ab-SA conjugate in CD45þ tissues, therapeutic radiobiotin
is administered and attaches to the pretargeted Ab-SA
conjugate bound speciﬁcally to tumor cells, with
unbound radiobiotin rapidly excreted by the kidneys. We
have evaluated the safety of PRIT using an anti-CD45 Ab-
SA conjugate followed by 90Y-DOTA-biotin combined with
ﬂudarabine (FLU), 2 Gy total body irradiation (TBI) and
matched allogeneic HCT for patients with advanced acute
myeloid leukemia (AML), acute lymphoblastic leukemia
(ALL), or high-risk myelodysplastic syndrome (MDS).
Seven patients received trace labeled, dosimetric infu-
sions of 0.7 mg/kg anti-CD45 Ab-SA followed 48 hours
later by 1.3 mg/m2 of 111In-DOTA-biotin (5-10 mCi). The
biodistribution of 111In-DOTA-biotin was assessed by
serial planar gamma camera imaging at multiple time
points that revealed optimal targeting of leukemic target
tissues. Five patients then received 0.7 mg/kg anti-CD45
Ab-SA followed 48 hours later by 1.3 mg/m2 DOTA-biotin
labeled with a therapeutic amount of 90Y (62-112 mCi,
median 75 mCi) based on OLINDA organ based dosimetry
from the 111In-DOTA-biotin images. Of the two patients
who did not receive therapeutic infusions, one developed
cellulitis and the other was diagnosed with bladder
carcinoma. Approximately one week after 90Y-DOTA-
biotin PRIT, FLU was administered at 30 mg/m2/day for 3
consecutive days followed by TBI at a dose of 2 Gy (6-7
cGy/min) and then infusion of >2 x 106 CD34-expressing
peripheral blood stem cells/kg body weight. Two grade 3
gastrointestinal adverse events (enterocolitis, typlitis)
were identiﬁed as unexpected and considered possibly
related to PRIT, with the only grade 4 event being
cytopenias that are expected during HCT. No participants
were withdrawn from the study due to toxicities. One of
the 5 high-risk AML/MDS patients enrolled remains alive
in complete remission a year after protocol treatment.
The other 4 patients died of progressive disease with
a median time to relapse of 28 days (range 12-155).
Whether this approach will reduce post-transplant
relapse remains to be determined, but further dose
escalation is clearly necessary.29
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Invasive fungal infections (IFI) are associated with a high
mortality rate in patients undergoing hematopoietic stem
cell transplantation (HSCT). However, with availability of
new antifungal agents with lower toxicity proﬁles and
implementation of reduced intensity transplants (RIT),
patients with previously documented, proven or probable IFI
are increasingly undergoing HSCT. Recognizing these prac-
tice changes, the clinical outcomes of patients with pre-
existing IFI, diagnosed prior to allogeneic HSCT, (n¼ 825)
were compared to a similar cohort of patients from the same
HSCT centers over the past decade without proven or prob-
able pre-transplant IFI (n¼10,247), for outcomes of treat-
ment related mortality (TRM), relapse rates, overall survival
(OS), disease free survival (DFS) and the development of
post-transplant IFI. Primary analysis focused on outcomes
